PreveCeutical Medical (TSE:PREV) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board, bringing his expertise in venture capital and corporate development. Gallagher’s extensive experience in biotech investments and successful leadership in high-profile exits, like the acquisition of Translate Bio by Sanofi, is expected to drive BioGene’s growth in innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.